FaithEDaviesMD

PubMed

• 733 citations
  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
  Faith E. Davies, Noopur Raje, Teru Hideshima, Suzanne Lentzsch, Gloria Young
  Blood. 2001-07-01
• 54 citations
  Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib
  Timothy J. Graham, Gary Box, Nina Tunariu, Mateus Crespo, Terry J. Spinks
  Journal of the National Cancer Institute. 2014-04-01
• 144 citations
  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage
  Andy C. Rawstron, Roger G. Owen, Faith E. Davies, Roderick J. Johnson, Richard A. Jones
  British Journal of Haematology. 1997-04-01

Journal Articles

• Sub-Clonal TP53 Copy Number Is Associated with Prognosis in Multiple Myeloma  
  Faith Davies, MD, Blood
• Characterisation of Immunoparesis in Newly Diagnosed Myeloma and Its Impact on Progression-Free and Overall Survival in Both Old and Recent Myeloma Trials  
  Faith Davies, MD, Nature

Abstracts/Posters

• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blow...
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Current Obstacles in Myeloma Management: Debating the Evidence 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Characterisation of Long-Term Responders to First-Line Myeloma Therapy – Results from the UK Myeloma IX and XI Trials 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Future Monoclonal Antibodies: BCMA and Beyond 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all